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Fluid clearanceActive Na+ absorption by alveolar ENaC is the main driving force of liquid clearance at birth and lung edema
resorption in adulthood. We have demonstrated previously that long-term modulation of KvLQT1 and KATP
K+ channel activities exerts sustained control in Na+ transport through the regulation of ENaC expression
in primary alveolar type II (ATII) cells. The goal of the present study was: 1) to investigate the role of the
α-ENaC promoter, transfected in the A549 alveolar cell line, in the regulation of ENaC expression by K+ chan-
nels, and 2) to determine the physiological impact of K+ channels and ENaC modulation on ﬂuid clearance in
ATII cells. KvLQT1 and KATP channels were ﬁrst identiﬁed in A549 cells by PCR and Western blotting. We
showed, for the ﬁrst time, that KvLQT1 activation by R-L3 (applied for 24 h) increased α-ENaC expression,
similarly to KATP activation by pinacidil. Conversely, pharmacological KvLQT1 and KATP inhibition or silencing
with siRNAs down-regulated α-ENaC expression. Furthermore, K+ channel blockers signiﬁcantly decreased
α-ENaC promoter activity. Our results indicated that this decrease in promoter activity could be mediated,
at least in part, by the repressor activity of ERK1/2. Conversely, KvLQT1 and KATP activation dose-
dependently enhanced α-ENaC promoter activity. Finally, we noted a physiological impact of changes in
K+ channel functions on ERK activity, α-, β-, γ-ENaC subunit expression and ﬂuid absorption through polar-
ized ATII cells. In summary, our results disclose that K+ channels regulate α-ENaC expression by controlling
its promoter activity and thus affect the alveolar function of ﬂuid clearance.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
After birth, effective gas exchange in the lungs requires alveolar
air spaces virtually free of ﬂuid, except for the alveolar sub-phase lin-
ing the alveolar surface. Liquid clearance from the alveolus to the
interstitium is mainly driven by active ion transport across alveolar
epithelial cells. The crucial role of Na+ absorption in this process
has been demonstrated by several experimental lines of evidence in
animal models [1–5].
In alveolar epithelial cells, Na+ absorption depends on passive
entry through apical Na+ channels, including non-selective NSC
channels, highly Na+-selective HSC channels and cyclic nucleotide-
gated CNG channels. At the basolateral membrane, Na+/K+-ATPase3840, Saint-Urbain, Montréal,
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l rights reserved.is involved in active Na+ exit whereas K+ ions are recycled by K+
channels. NSC can be formed from α-ENaC subunits only, while HSC
are commonly described as heteromers of α-, β- and γ-ENaC subunits
[6,7]. A δ subunit, mainly expressed in the brain [8], has also, how-
ever, been identiﬁed in human lung and airway epithelial cells [9,10].
Among these various transport mechanisms, α-ENaC is a key
element for ﬂuid absorption at birth and for edema resorption in adult-
hood. Indeed, it has been shown that α-ENaC-deﬁcient (α-ENaC(−/−))
neonatal mice are unable to clear alveolar ﬂuid at birth and rapidly
die from respiratory distress [11]. Moreover, α-ENaC silencing with
siRNAs reduces basal alveolar ﬂuid clearance and prevents stimulation
by β-adrenoceptors [12]. β- and γ-ENaC also participate in alveolar
clearance, but seem less critical than α-ENaC in mice since β- and
γ-ENaC null neonates do not go into respiratory distress but probably
die from hyperkalemia [13,14].
Several strategies have been adopted to up-regulate ENaC activ-
ity and expression in an attempt to subsequently stimulate ﬂuid
clearance. ENaC activity can be directly modulated by cAMP or β-
adrenergic receptor agonists, for example, by increasing channel
open probability or the number of active channels at the plasma
membrane (for review see [15]). ENaC currents are also regulated
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ubiquitination mechanisms [16]. ENaC gene expression is mainly
regulated by glucocorticoids [17–19] and catecholamines [20].
Mouse, rat and human α-ENaC promoters [17,21,22] have been
cloned. The 2.9-kb α-ENaC promoter construct cloned from a
mouse genomic library [17], is fully functional and allows the modu-
lation of ENaC transcription by glucocorticoids and transforming
growth factor-beta (TGFβ) in alveolar and kidney cells, for exam-
ple [17,18,23,24]. Multiple consensus sequences for binding of tran-
scription factors have been identiﬁed on α-ENaC promoters.
Moreover, various signaling pathways, such as Ras [25], MEK/ERK
[23,25], p38 MAPK [26] and Smad [24], are involved in the regulation
of ENaC promoter activity by glucocorticoids [18,19,22,25], tumor
necrosis factor-alpha (TNFα) [18,27] or TGFβ [23,24], for example.
α-ENaC gene expression is thus controlled by a complex regulatory
system that requires further investigation.
Several functional pieces of evidence indicate that K+ channels
also contribute to the control of lung surface ﬂuid composition and
volume. For example, Sakuma et al. observed that KATP channel acti-
vation enhanced alveolar clearance in resected human lungs [28]. In
fact, K+ channels control membrane potential and maintain the driv-
ing force for transepithelial ion and liquid transport. In primary cul-
tured alveolar type II (ATII) cells, we have identiﬁed 3 types of K+
channels, i.e. KvLQT1, KATP and KCa3.1 [29,30]. Our results have
revealed that KvLQT1 and KATP channels contribute to a major part
of K+ currents through the basolateral membrane of alveolar cells
in resting conditions [31]. We have determined that acute application
of KvLQT1 and KATP channel modulators modiﬁes Na+ and Cl− trans-
epithelial currents, measured in Ussing chambers [29]. Interestingly,
we have also observed that long-term modulation of K+ channels
(24-h treatments with KvLQT1 and KATP modulators) not only regu-
lates Na+ currents but also controls ENaC mRNA and protein expres-
sion in ATII cell monolayers [30].
We decided to further study the regulatory mechanisms of α-
ENaC mRNA expression, particularly through changes in α-ENaC pro-
moter activity, after modulation of KvLQT1 and KATP channels. Be-
cause transfection efﬁciency of the promoter constructs in primary
cultured ATII cells was too low, we focused on A549 cells, a human al-
veolar epithelial cell line with characteristics of ATII cells [19,32,33].
We ﬁrst checked for the presence of KvLQT1 and KATP channels in
these cells and tested the effects of pharmacological inhibitors and ac-
tivators of these channels on α-ENaCmRNA expression. In addition to
the KATP channel activator pinacidil [29,30], a KvLQT1 activator
(R-L3 [34–36]) that has never been investigated in alveolar ion
transport, was used. To provide direct evidence of the role of K+
channels, we also took a molecular approach involving KvLQT1
and KATP silencing with speciﬁc siRNAs. The impact of K+ channel
modulation on α-ENaC promoter activity was then evaluated after
transient transfection of a plasmid containing the 2.9-kb α-ENaC
promoter cloned upstream of the ﬁreﬂy luciferase (Luc) reporter
gene [17,18]. The mechanisms whereby changes in K+ ﬂuxes mod-
ulate α-ENaC promoter expression, especially MAPK signaling path-
ways, were then investigated. Finally, we veriﬁed the physiological
impact of changes in K+ channel functions on ERK activity, α-,
β- and γ-ENaC subunit expression, and liquid absorption through
polarized ATII cell monolayers.
2. Materials and methods
2.1. Alveolar A549 cell culture
Alveolar epithelial A549 cells were maintained in Dulbecco's mod-
iﬁed Eagle's medium (DMEM, Gibco™, Invitrogen, Burlington, ON)
with 10% fetal bovine serum (FBS, Gibco™, Invitrogen), 2 mM gluta-
mine (Gibco™, Invitrogen), 50 U/ml penicillin and 50 μg/ml strepto-
mycin (Gibco™, Invitrogen).2.2. ATII cell isolation and primary culture
ATII cells were isolated from adult male Sprague–Dawley rats
(6–7 weeks), according to a well-established protocol [29–31,37]. In
brief, the lungs were washed to remove blood cells and alveolar
macrophages before treatment with elastase (Worthington, Free-
hold, NJ). They were then minced, and the resulting suspension
was ﬁltered. Alveolar cells were collected and puriﬁed by a differen-
tial adherence technique [38], which enhanced the purity of the ATII
cell pool to 86% [29,37]. This freshly-isolated cell suspension was
cultured on permeant ﬁlters (Costar Transwell, Toronto, ON) in
MEM (Gibco™, Invitrogen) containing 10% FBS (Gibco™, Invitrogen),
0.08 mg/l gentamicin, septra (3 μg/ml trimethoprime+17 μg/ml sul-
famethoxazole), 0.2% NaHCO3, 10 mM HEPES and 2 mM L-glutamine,
as described previously [29,30]. Thirty-six h after seeding, the cul-
ture medium on the apical side of the alveolar epithelial monolayers
was removed to create an air–liquid interface (ALi) and the basolat-
eral MEM-FBS-septra medium was replaced on day 3 by MEM-FBS
without septra.2.3. PCR ampliﬁcations of ion channels
Five μg of total RNA puriﬁed from A549 cells with TRIzol reagent
according to the manufacturer's instructions (Invitrogen), were
reverse-transcribed to cDNA with MMLV reverse transcriptase (RT,
Invitrogen) in the presence of oligodT primers. cDNAs were ampliﬁed
with Taq polymerase (Invitrogen) and speciﬁc primers designed from
sequences of the following cloned human channels: hKvLQT1 (Kv7.1
[39], NM_000218, 5′taaggaagagcccaacactg3′, 5′cgatccttgctcttttctga3′,
1 μM ﬁnal concentration of each, 355-bp PCR product), hKATP
(Kir6.1 [40], NM_004982, 5′ttcaccaactggacattcct3′, 5′tttggtaccatgagg-
gaaga3′, 1 μM, 499-bp PCR product) and hα-ENaC ([41], NM_001038,
5′aacaaatcggactgcttctac3′, 5′agccaccatcatccataaa3′, 1 μM, 406-bp PCR
product). Finally, the hβ-actin primer pair (5′agagctacgagctgcctgac3′
and 5′aaagccatgccaatctcatc3′, 0.25 μM) ampliﬁed a 499-bp product.
Primer pairs were designed in distinct exons to avoid genomic
DNA ampliﬁcation. RT-PCR ampliﬁcation was undertaken according
to a well-established laboratory protocol [18,30]. Brieﬂy, the cDNA
ampliﬁcation curve was ﬁrst charted for each primer pair to deﬁne
the optimum number of cycles in the linear phase of ampliﬁcation.
The hKir6.1 product was ampliﬁed for 32 cycles, hKvLQT1 and hα-
ENaC for 26 cycles, while β-actin ampliﬁcation was stopped after
18 cycles. Since β-actin ampliﬁcation remains stable under all tested
conditions, even in the linear phase of ampliﬁcation [18,30], PCR
products were normalized with the β-actin signal for each cDNA
sample. The RT-PCR products were ﬁnally separated on agarose
gels, stained with SYBR Safe (Invitrogen) and analyzed with Ty-
phoon Gel Imager [18,30].
Total RNA from rat primary ATII cells on permeant ﬁlters was
puriﬁed with TRIzol™ reagent. For cDNA synthesis, 1 μl of random
primer (200 ng/μl, Roche, Indianapolis, IN) and 1 μl dNTPs
(10 mM) were added to 1 μg of total RNA in 10 μl H20. After heat-
ing for 5 min at 65 °C and 3-min incubation on ice, 4 μl of 5× ﬁrst
strand buffer, 2 μl of 0.1 M DTT, 1 μl of RNase-out (Invitrogen) and
1 μl of MMLV reverse transcriptase (Invitrogen) were added. The
reaction was incubated for 10 min at 25 °C for annealing of the
primers, then for 50 min at 37 °C for cDNA synthesis. The reaction
was stopped by 15-min incubation at 70 °C. For the qPCR ampliﬁca-
tion, 15 ng of cDNA were ampliﬁed with forward and reverse primers
at 225 nM each with Platinium SYBR Green qPCR superMix-UDG
(Invitrogen) in a ﬁnal volume of 15 μl. For α-ENaC (Scnn1a gene,
NM_031548, 5′cgtcactgtctgcaccctta3′, 5′cctggcgagtgtaggaagag3′), β-
ENaC (Scnn1b gene, NM_012468, 5′tacagtccctgcaccatgaa3′, 5′tggat-
catgtggtcttggaa3′) and γ-ENaC (Scnn1g gene, NM_017046, 5′ccaatg-
tatgggaactgctac3′, 5′gacttgcagcccgtactc3′), the amplicon sizes were
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tion of sample to sample variations. The amplicon size of 5S rRNA was
115 bp (NR_033176, 5′acagccataccaccctgaac3′, 5′aagcctacagcacccgg-
tat3′). qPCRs were ampliﬁed in a Rotor-Gene Q5 Plex (Qiagen, Toronto,
ON). After 10-min 95 °C incubation to activate Taq polymerase, the
samples were ampliﬁed for 40 cycles with a 10-s denaturation step at
95 °C, a 15-s annealing step at 58 °C and a 20-s elongation step at
72 °C. A high resolution melting curve was generated at the end of
ampliﬁcation to assess the nature of the amplicon. Standard cDNA
was also run in parallel to the samples tested in duplicate, to nor-
malize the ampliﬁcation signal from run to run. For quantitative
analysis, the ﬂuorescence signal of dsDNA with SYBR Green was
converted in a gene copy number calculated from the dilution
curve of the standard reaction. The expression of a given gene was
reported as a percentage compared to untreated cells obtained
from the same animal.2.4. K+ channel silencing with siRNA
40,000 A549 cells were plated in Petri dishes (35 mm) and cul-
tured for 72 h in DMEM, 10% FBS and 2 mM L-glutamine (until they
reached 40–50% conﬂuence). DMEM was then replaced by OptiMEM.
siRNAs were mixed with Lipofectamine™ RNAiMAX transfection re-
agent (Invitrogen) in OptiMEM. The siRNA-RNAiMAX mix was
added drop by drop to the cells after 20-min incubation at room tem-
perature. Fresh medium (DMEM, 10% FBS and 2 mM L-glutamine)
was added onto cells after 5 h of transfection. The medium was
replaced every day for 72–96 h.
Fluorescent GAPDH siRNA (100 pmol/well, Silencer® Cy™-3-
Labeled GAPDH siRNA, Ambion Inc, Austin, TX) served to verify the
transfection efﬁciency of siRNA in A549 cells. In the experimental
conditions described above, we observed >90% ﬂuorescent-positive
A549 cells. In subsequent experiments, the cells were transfected
with stealth™ siRNA duplex oligonucleotides targeting KvLQT1
(Kcnq1-HSS142716, Invitrogen, 100 pmole) and Kir6.1 (Kcnj8-
HSS105727, Invitrogen, 50 pmole). Stealth RNAi negative control
(12935–400, Invitrogen) and Mission siRNA Universal negative con-
trol #1 (SIC001, Sigma-Aldrich, St-Louis, MO) were employed as neg-
ative controls, in KvLQT1 and Kir6.1 siRNA experiments, respectively.
KvLQT1 and KATP (Kir6.1) silencing was then veriﬁed by measuring
KvLQT1 and Kir6.1 mRNA by PCR.2.5. Transient transfection of αENaC promoter and Luc assay
Alteration of α-ENaC promoter activity by K+ channel modula-
tors was tested in A549 cells, which were transiently transfected
with a 2.9-kb BamHI-MscI fragment of the mouse α-ENaC promoter
[17,18,27] cloned upstream of the ﬁreﬂy Luc reporter gene (αENaC-
Luc). pRL-SV40 (Promega, Madison, WI), a plasmid expressing
Renilla reniformis luciferase, was co-transfected for normalization
of the Luc response. Seventy-two h prior to transfection, 20,000
cells were plated in 1.9 cm2 wells of 24-well plates and cultured
without antibiotics in DMEM, 10% FBS and 2 mM L-glutamine. For
each well, 500 ng of α-ENaC-Luc plasmid was mixed with 800 pg
pRL-SV40 and 1.5 μl FuGENE® HD transfection reagent (Roche) in
200 μl OptiMEM. The mix was incorporated drop by drop after
20-min incubation at room temperature. After 5 h, the transfection
medium was replaced by a fresh medium (DMEM+antibiotics)
with or without ERK or p38 inhibitor. One h later, K+ channel mod-
ulators were included for another 24 h. Fireﬂy and Renilla luciferase
assays were then undertaken with the Dual-Luciferase Reporter
Assay System as speciﬁed by the manufacturer (Promega). Lumino-
metry was performed in a Synergy 2 luminometer (BioTek Instru-
ments, Winooski, VT).2.6. Immunoblotting
Total proteins were solubilized in lysis buffer [150 mM NaCl,
50 mM Tris·HCl, pH 7.6, 1% Triton X-100, 0.1% SDS, protease inhibitor
cocktail (Complete Mini EDTA-free protease inhibitor cocktail, Roche,
Mannheim, Germany)] for 30 min on ice and centrifuged at 12,000 g
for 15 min. The supernatants were collected, and protein content
was measured. After denaturation (at 95 °C for 5 min in 2× sample
buffer (62.5 mM Tris·HCl, pH 6.8, 2% SDS, 10% glycerol, 0.2% bromo-
phenol blue, 4% β-mercaptoethanol)), proteins (60–100 μg) were
separated by SDS-PAGE (7.5%) and transferred onto nitrocellulose
membranes. The membranes were ﬁrst blocked with 10% dried fat-
free milk (or 4% BSA) in TBST for 1 h at room temperature, then in-
cubated with commercial anti-KvLQT1 (dilution 1:1,000, sc-10645,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, recognizing a ~75-
kDa band), anti-Kir6.1 (dilution 1:200, sc-11224; Santa Cruz Biotech-
nology, Inc., ~50-kDa band), anti-ERK1/2 (1:1,000, Cell Signaling
Technology, Danvers, MA, 42- and 44-kDa proteins), anti-phospho-
ERK1/2 (1:1,000, Cell Signaling Technology), anti-p38 (1:1,000, Cell
Signaling Technology, 38-kDa band), anti-phospho-p38 (1:1,000,
Cell Signaling Technology), in TBST plus 10% milk or 2% BSA, over-
night at 4 °C. After washing with TBST, the membranes were incubat-
ed with donkey anti-goat (for KvLQT1 and Kir6.1; 1:2,000, Santa Cruz
Biotechnology, Inc.), goat anti-rabbit (for ERK1/2, p-ERK1/2, p38 and
p-p38, 1:2,000; Bio-Rad, Mississauga, ON) or horse anti-mouse (for β-
actin; 1:3,000, Cell Signaling Technology, 42-kDa) IgG linked to
horseradish peroxidase for 1 h. The speciﬁcity of anti-Kir6.1 and
-KvLQT1 antibodies was veriﬁed with their respective blocking pep-
tide (sc-11224P, sc10645P, Santa Cruz Biotechnology, Inc.) [30,31].
Ponceau staining was also performed, and β-actin protein was
revealed (on the same blot) with a puriﬁed mouse anti-β-actin
monoclonal antibody (dilution 1:2,500, 90 min at room temperature,
CLT9001, Cedarlane Laboratory Limited, Burlington, ON) to ensure
equivalent loading. The intensity of each speciﬁc band was quantiﬁed
with Multigauge software and normalized to the β-actin signal.
2.7. Fluid transport across alveolar epithelial cell monolayers
Fluid transport across alveolar cell monolayers was measured
according to a method adapted from Fang et al. [42], with FITC-
labeled dextran (150-kDa, FD150S, Sigma-Aldrich) as volume marker.
As described previously [18,30], alveolar epithelial cell monolayers
were cultured at the ALi on 1.1 cm2 permeant ﬁlters (Costar Trans-
well), before the addition, on day 4, of 0.6 ml of culture medium
(MEM-10% FBS) containing 0.2 mg/ml FITC-dextran to the apical
side of the monolayers. At the same time, the monolayers were trea-
ted with ion channel modulators: amiloride was added on the apical
side in FITC-dextran containing MEM, while cloﬁlium, glibenclamide,
pinacidil and/or R-L3 were applied on the basolateral side of the
monolayers. The cells were then incubated at 37 °C with 5% CO2 in a
humidiﬁed incubator. After 5 min (“t5”), 100 μl of the apical and
100 μl of the basolateral medium (corresponding to the initial sam-
ple) were collected. The monolayers were then placed in a humidiﬁed
incubator for a 24-h period (“duration”), when 100-μl aliquots of api-
cal and basolateral media were collected (“t24”). Measurements were
recorded in triplicate (3 samples/ﬁlter), in 2 ﬁlters per condition, to
minimize possible variability. The FITC signal (Ex: 495, Em: 517), in
each “t5” and “t24” sample was quantiﬁed with a Synergy 2 lumin-
ometer (BioTek Instruments). Fluid transport was calculated accord-
ing to the following formula: ﬂuid absorption (μl.cm−2.h−1)=
[1−(ﬂuorescence of “t5” sample/ﬂuorescence of “t24” sample)]×initial
apical volume/surface of the ﬁlter/“duration”. Permeability to protein
(Pp) was also estimated in each monolayer, by measuring the FITC
signal in the basolateral medium. Monolayers with Pp >3% were
discarded. The absence of free FITC (unbound to dextran) was
veriﬁed by measuring FITC signal (b1%) in the supernatant, after
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Fig. 2. Modulation of α-ENaC mRNA expression by K+ channel modulators in A549
cells. A549 cells were cultured until conﬂuency and treated for 24 h with R-L3 (RL, a
KvLQT1 activator, 4 μM), pinacidil (Pina, a KATP activator, 100 μM), or a combination
of these activators (RL+Pina), cloﬁlium (Cloﬁ, a KvLQT1 inhibitor, 5 μM), glibencla-
mide (Glib, a KATP inhibitor, 50 μM), a combination of these inhibitors (Cloﬁ+Glib)
or iberiotoxin (Iberio, a BKCa inhibitor, 100 nM). The data are presented as percentages
of α-ENaCmRNA expression of control untreated monolayers (Ctl), after normalization
with β-actin. Representative gels are also presented. Cells from at least 4 different pas-
sages (n>4) were used for each experimental condition. * Pb0.04.
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measured in an empty, paraﬁlm-sealed Transwell membrane, was
null.
2.8. Statistics
Average values are given as means±SE. n represents the number
of experiments that were performed on at least 4 different passages
or animals. Comparisons between groups were made by paired or
1-group t-test with Statview software (SAS Institute, Cary, NC). A
probability of Pb0.05 was considered to be signiﬁcant (P values
were reported for each experiment.).
3. Results
3.1. Evidence of KvLQT1 and KATP channels in A549 alveolar
epithelial cells
KvLQT1 and KATP (Kir6.1) channels, identiﬁed previously in ATII
cells [29–31], were evaluated in alveolar A549 cells. Primer pairs,
designed fromKvLQT1 (Kv7.1, Kcnq1) and Kir6.1 (Kcnj8), respectively,
ampliﬁed 355- and 499-bp products from A549 cDNAs, as expected
(Fig. 1), demonstrating their presence in these cells. Expression of
KvLQT1 (~75 kDa) and Kir6.1 (~50 kDa) proteins was conﬁrmed by
Western blotting (Fig. 1).
3.2. Regulation of α-ENaC expression by pharmacological modulators
of K+ channels
We reported previously that changes in KvLQT1 and KATP activities
induced sustained regulation of Na+ transport and ENaC mRNA and
protein expression in primary ATII cells [30]. We now evaluated alter-
ations of α-ENaC mRNA expression in A549 cells, after modulation of
KvLQT1 and KATP with various pharmacological agents, including
the KvLQT1 activator benzodiazepine R-L3 (L-364,373 [(3-R)-1,3-
dihydro-5-(2-ﬂuorophenyl)-3-(1H-indol-3-ylmethyl)-1-methyl-2H-
1,4-benzodiazepine-2-one], provided through aMerckMaterial Transfer
Agreement). This drug has been shown to stimulate IKs currents
through KvLQT1 channels [35,36]; however, the effect of KvLQT1 acti-
vation on ENaC regulation has never been tested before. RT-PCR exper-
iments revealed that R-L3 application (4 μM, 24 h) elicited a 22.2±6.5%
increase in α-ENaC mRNA expression, (Pb0.02, n=8, Fig. 2), whilekDa
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Fig. 1. Identiﬁcation of KvLQT1 and KATP channels in A549 alveolar epithelial cells.
Agarose gels showing RT-PCR products, ampliﬁed from A549 cell cDNA with PCR primer
pairs designed from human KvLQT1 (A, left panel) and KATP (Kir6.1, B, left panel). Detec-
tion of KvLQT1 (A, right panel) and Kir6.1 (B, right panel) proteins by Western blot
analysis of representative A549 cell lysates.pinacidil (KATP activator, 100 μM, 24 h) stimulated α-ENaC expression
by 34±4% (Pb0.007, n=7, Fig. 2), compared to untreated A549mono-
layers. R-L3 and pinacidil, applied in combination, did not have an addi-
tive effect (Fig. 2).
The impact of K+ channel inhibitors was then tested. Twenty-
four-h treatment with cloﬁlium (5 μM), an inhibitor of KvLQT1, re-
duced α-ENaC expression by 29.2±3.7% (Pb0.0002, n=7, Fig. 2).
Glibenclamide (50 μM), a KATP inhibitor, elicited a similar effect
(36±6% decrease, Pb0.001, n=7, Fig. 2). Cloﬁlium and glibencla-
mide applied in combination (Fig. 2) produced a decline of α-ENaC
mRNA expression (39±10% inhibition, Pb0.04, n=4, Fig. 2), not sig-
niﬁcantly different from cloﬁlium and glibenclamide alone. Because
large conductance Ca2+-activated K+ channels (BKCa) have been
identiﬁed in A549 cells [43,44], we also tested the effect of BKCa
inhibition and found that iberiotoxin (100 nM) failed to modulate
α-ENaC mRNA expression (Fig. 2).
3.3. Inhibition of α-ENaC mRNA expression after KvLQT1 and
KATP silencing
Because nonspeciﬁc effects of pharmacological drugs cannot be
totally ruled out, KvLQT1 (siKvLQT1) or Kir6.1 (siKir6.1) stealth siR-
NAs were deployed speciﬁcally to silence these channels and to
test if their extinction subsequently affected α-ENaC expression.
The silencing efﬁciencies of KvLQT1 and Kir6.1 channel siRNAs
were veriﬁed ﬁrst. KvLQT1 and Kir6.1 mRNA expression was mark-
edly decreased (~60% inhibition, Pb0.0002, n=8, Figs. 3A and B)
in 72 h post-transfection by their corresponding siRNAs. α-ENaC
mRNA expression (Fig. 3C) was signiﬁcantly reduced in A549
monolayers transfected with KvLQT1 (siKvLQT1, 71±9% of control,
Pb0.05, n=7, left panel) and Kir6.1 (siKir6.1, 65±10%, Pb0.02,
n=6, right panel) siRNAs compared to monolayers transfected
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Fig. 3. Down-regulation of α-ENaC mRNA expression after KvLQT1 and KATP silencing
in A549 cells. A549 cells (at 40–50% conﬂuency) were transiently transfected with siR-
NAs against KvLQT1 (siKvLQT1, 100 pmole), Kir6.1 (siKir6.1, 50 pmole) or RNAi nega-
tive controls (siCtl), with RNAiMax transfecting agent. RNA was extracted after 72 h of
transfection. Efﬁciency of KvLQT1 and Kir6.1 silencing, by their corresponding siRNAs,
was veriﬁed by measuring inhibition of KvLQT1 (A) and Kir6.1 (B) expression (normal-
ized with β-actin and represented as % of control monolayers treated with siCtl). α-
ENaC mRNA expression was also measured in KvLQT1 or Kir6.1 siRNA-treated mono-
layers (represented as % of control monolayers treated with siCtl after normalization
with β-actin, C). Representative agarose gels are also presented. At least 6 different ex-
periments were undertaken for each experimental condition. *Pb0.05.
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Fig. 4. Stimulation of α-ENaC promoter activity after K+ channel activation in A549
cells. A549 cells were transiently co-transfected with a construct containing the
α-ENaC promoter upstream of luciferase (Luc) and with the pRL-SV40 vector coding
for Renilla reniformis luciferase (RL) for normalization of the Luc signal. After 6 h of
transfection, the cells were cultured for 24 h in DMEM or treated for 24 h with 0.5, 2,
4 or 10 μM R-L3 (A) or 5, 10, 25 or 100 μM pinacidil (B). α-ENaC promoter activity is
presented as % of untreated control cells. * Pb0.05. Mean values represent a minimum
of 5 experiments in triplicate for each condition.
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ment of K+ channels in the control of α-ENaC mRNA expression.
3.4. Stimulation of the α-ENaC promoter after K+ channel activation
To further study the regulatory mechanisms of α-ENaC expres-
sion, we decided to evaluate the impact of KvLQT1 and KATP channel
modulation on α-ENaC promoter activity. A549 cells were co-
transfected with the α-ENaC-Luc construct containing a functional
2.9-kb α-ENaC promoter cloned upstream of the ﬁreﬂy Luc gene
[17,18,27] and with the pRL-SV40 plasmid expressing Renilla renifor-
mis luciferase (RL) that allow normalization of the Luc response. As il-
lustrated in Fig. 4A, R-L3 dose-dependently stimulated α-ENaC
promoter activity (1.6- and 2.2-fold increases at 4 and 10 μM R-L3,
Pb0.03). Similarly, pinacidil signiﬁcantly enhancedα-ENaC promoter ac-
tivity (1.3- and 1.5-fold increment at 10 μM and 100 μM, Pb0.04, Fig. 4B).
3.5. Regulation of α-ENaC promoter activity after K+ channel inhibition
and potential signaling pathways
As reported in Fig. 5A, combined inhibition of KvLQT1 and KATP
channels elicited a decrease in α-ENaC promoter activity (43±8%decrease, Pb0.001, column 5). We then investigated the intracellular
signaling pathways whereby K+ channel activity could control α-
ENaC expression. Because ENaC expression is regulated by p38 and
ERK1/2 MAPKs [23,26,45,46] and Kv and KATP K+ channel activities
could affect these signaling proteins [47–49], we decided to explore
their roles in the control of α-ENaC by K+ channels. Inhibition of
p38 and ERK1/2, with SB203580 (25 μM) and PD98059 (20 μM) re-
spectively, enhanced basal α-ENaC promoter activity by 1.36-fold
(column 2, Pb0.001) and 1.57-fold (column 3, Pb0.04), respectively,
while combined inhibition of both MAPKs increased it by 2.50-fold
(column 4, Pb0.02), indicating repressive activity of these MAPKs
on the α-ENaC promoter. We observed that combined inhibition of
p38 and ERK1/2 also augmented α-ENaC promoter activity measured
after K+ channel inhibition (compare columns 5 and 6, n=9,
Pb0.001).
To determine if the down-regulation of α-ENaC promoter activity
after K+ channel inhibition could be mediated by repressor activity of
p38 and/or ERK1/2, we tested the effects of cloﬁlium and glibenclamide
blockers on these MAPKs. As observed in Fig. 5B, p38 phosphorylation
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channel inhibitors, indicating that α-ENaC regulation by K+ channels
is probably independent of p38 signaling. In contrast, phospho-
proteins p42 and p44 (ERK1/2) were signiﬁcantly increased after expo-
sure to K+ channel blockers (1.8-fold rise in the pERK/ERK ratio at
15 min and 2.4-fold increment at 45 min and 3 h, compared to the con-
trols, Fig. 5C). Altogether, these data suggest that the inhibitory out-
come of K+ channel blockers could be due, at least in part, to the
repressor activity of ERK1/2 on the α-ENaC promoter.
3.6. Physiological impact of K+ channel modulation on ENaC expression
and alveolar ﬂuid clearance through ATII cell monolayers
Similarly to A549 cells, inhibition of KvLQT1 and KATP channels in po-
larized primary ATII cells cultured on permeant ﬁlters also elicited strong
activation of ERK1/2 at 15 min and 45 min (Fig. 6A). In addition, K+ chan-
nel inhibition signiﬁcantly decreased α-, β- and γ-ENaC subunit mRNA
expression.We also conﬁrmed a signiﬁcant activation ofα-ENaC expres-
sion by K+ channel activators, while β- and γ-ENaC subunit mRNAexpression were slightly but not signiﬁcantly stimulated (Fig. 6B). We
thus hypothesized that changes in K+ channel functionmayhave a phys-
iological impact on liquid absorption, which is dependent, in large part
(~50–60%), on Na+ transport through ENaC. Fluid absorption from the
apical to the basolateral side of ATII cell monolayers, cultured for 4 days
at the ALi, was measured with FITC-dextran as volume marker, for 24 h
(Fig. 6C, D). Mean liquid absorption in non-treated monolayers was
1.44±0.11 μl.cm−2.h−1 (n=7). Consistent with the stimulation of
ENaC expression by pinacidil, this KATP opener also heightened ﬂuid ab-
sorption by 32±7% (Pb0.02), while R-L3 enhanced it by 45±9%
(Pb0.002). Combined treatment with both activators elicited an effect
similar to that of R-L3 alone (41±8% increase, Pb0.004). In contrast,
combined KvLQT1 and KATP channel inhibition resulted in a 71% decrease
in liquid clearance (Cloﬁ+Glib, Fig. 6B, n=6, Pb0.002). It should be
noted that this inhibition is slightly, but not signiﬁcantly higher than
that observed after amiloride (10 μM) treatment (54% inhibition,
n=6). Furthermore, combined application of K+ channel blockers with
amiloride did not further reduce alveolar absorption, compared to K+
channel inhibitors alone (Fig. 6B), indicating a common pathway.
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This study ﬁrst demonstrated that KvLQT1 and KATP modulation
regulated A549 α-ENaC mRNA expression and α-ENaC promoter ac-
tivity. Our data also conﬁrmed the repressor activity of ERK and
showed ERK1/2 activation after treatment with K+ channel blockers,
indicating that this MAPK could be involved, at least in part, in α-
ENaC regulation by K+ channels. Finally, we demonstrated the phys-
iological impact of changes in K+ channels on α-, β- and γ-ENaC sub-
unit expressions and alveolar ﬂuid clearance in polarized ATII cells.
The observed stimulatory effect of the KATP activator pinacidil on
α-ENaC mRNA expression in A549 cells is in agreement with our pre-
vious results [30]. In addition, our ﬁndings demonstrate, for the ﬁrst
time, that KvLQT1 activation with R-L3 signiﬁcantly stimulates α-
ENaC mRNA expression, whereas its expression was reduced by
KvLQT1 or KATP inhibition, indicating that K+ channel activities con-
trol α-ENaC. We are aware that some K+ modulators lack speciﬁcity.
Glibenclamide, for example, blocks KATP [31] as well as CFTR channels.
However, CFTR has not been identiﬁed in A549 cells, suggesting that
the observed effects of glibenclamide reported in that study are spe-
ciﬁc to KATP. We cannot, however, completely rule out a nonspeciﬁcaction of the pharmacological agents. However, our complementary
molecular approach with siRNAs conﬁrmed the role of K+ channels
in the control of α-ENaC expression. It should be noted that the ob-
served inhibition of α-ENaC expression is only partial. This effect
could be explained for example, by partial K+ channel silencing. The
involvement of other K+ channels as well as other intrinsic and ex-
trinsic factors [50], in the control of ENaC expression, may be also
postulated. However, our data suggested that BKCa inhibition, for ex-
ample, did not affect α-ENaC mRNA expression.
To the best of our knowledge, our work provides the ﬁrst evidence
that KvLQT1 and KATP channels could control α-ENaC transcription
through its promoter activity. Moreover, we observed that ERK and
p38 inhibition enhances the α-ENaC promoter activity previously re-
duced by cloﬁlium and glibenclamide. These experiments, however,
did not allow us to deﬁne if the repressors ERK and p38 could be in-
volved in α-ENaC down-regulation after K+ channel inhibition. In
fact, no p38 activation was seen with 15-min to 3-h cloﬁlium and
glibenclamide treatments, indicating that the effect of K+ channels
on α-ENaC is probably independent of the p38 pathway. In contrast,
K+ channel inhibition was accompanied by ERK1/2 activation in
both A549 and ATII cells. These data suggested that ERK1/2 activation,
1689O. Bardou et al. / Biochimica et Biophysica Acta 1818 (2012) 1682–1690after K+ channel inhibition, could be, at least in part, responsible for
the decrease in α-ENaC promoter activity. A relationship between
K+ channels, the ERK1/2 MAPK pathway and α-ENaC expression is
supported by other data from the literature. Indeed, it has been
reported that K+ channels could modify ERK signaling [47,49,51]. In
addition, up- [26,45] or down-regulation [23,25,46,52] of ENaC ex-
pression through ERK1/2 and p38 activation, have been reported,
depending on cell types and external stimuli. In fact, many other
pathways or signals could be involved in ENaC control by K+ chan-
nels. For example, variations of intracellular K+ concentration have
been identiﬁed as regulators of gene expression and protein synthesis
[53]. In addition, changes in K+ ﬂuxes could modify the electrochem-
ical gradient and affect the transport of other ions, including Ca2+,
which control several transcription factors [54]. Promoter activity
was evaluated in that study with a functional 2.9-kb construct of
the mouse α-ENaC promoter [17,18], including multiple consensus
sequences for binding of several transcription factors. To date, we
do not know which transcription factor could be involved in the con-
trol of α-ENaC promoter activity after changes in K+ channel ﬂuxes.
In agreement with changes in α-ENaC promoter activity and ENaC
mRNA expression after K+ channel modulation; our study also dem-
onstrated a physiological impact on liquid transport in polarized pri-
mary ATII cell monolayers. The observed enhancement of ﬂuid
absorption with pinacidil is consistent with a previous study report-
ing increased alveolar ﬂuid clearance with the KATP activator YM-
934 in resected human lungs [28]. In addition, we demonstrated, for
the ﬁrst time, that KvLQT1 activation also promoted liquid absorp-
tion. Conversely, the reduction of alveolar liquid clearance, after
KvLQT1 and KATP inhibition, conﬁrms the role of these channels in
that phenomenon. It has to be noted that alveolar clearance in the
presence of K+ channel blockers is not further decreased by the addi-
tion of 10 μM amiloride, indicating that ENaC function is already
down-regulated after K+ inhibition.
5. Conclusions
Our study, via complementary pharmacological and molecular ap-
proaches, shows, for the ﬁrst time that KvLQT1 and KATP channels con-
trol α-ENaC expression through the regulation of its promoter activity.
Moreover, K+ channel activity is involved in alveolar liquid absorption,
probably via the regulation of Na+ channels. Pharmacological modula-
tion of K+ channels could thus be identiﬁed as a strategy to promote al-
veolar clearance and lung edema resorption.
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